Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.030 -0.070 (-1.15%)
Official Closing Price Updated: 8:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 694,137
Open 6.030
Bid (Size) 6.060 (1)
Ask (Size) 6.200 (1)
Prev. Close 6.100
Today's Range 5.810 - 6.100
52wk Range 4.810 - 13.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
From Pomerantz LLP
Via GlobeNewswire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Highlights Clinical and Regulatory Milestones, Prepares for Upcoming Catalysts
Via Investor Brand Network
Topics Intellectual Property

Performance

YTD
-35.9%
-35.9%
1 Month
-0.2%
-0.2%
3 Month
-28.7%
-28.7%
6 Month
-18.0%
-18.0%
1 Year
-43.0%
-43.0%

More News

Read More
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
From Pomerantz LLP
Via GlobeNewswire
CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives to Present at TD Cowen Neuropsychiatry & Epilepsy Summit
Via Investor Brand Network
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Cybin Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
From Pomerantz LLP
Via GlobeNewswire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes Enrollment in Phase 2 CYB004 Study for Generalized Anxiety Disorder
Via Investor Brand Network
Topics Intellectual Property
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Participate in Cantor Global Healthcare Conference
Via Investor Brand Network
Cybin to Participate in the Cantor Global Healthcare Conference 2025
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Appoints Co-Founder Eric So as Interim CEO
Via Investor Brand Network
Cybin Announces Senior Leadership Changes
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Australian Approval to Begin EMBRACE Phase 3 Study of CYB003
Via Investor Brand Network
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Annual Meeting Voting Results
Via Investor Brand Network
Cybin Announces Results of Annual Meeting of Shareholders
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q1 2025 Results, Advances Phase 3 Depression Program and Nears Completion of Phase 2 Anxiety Study
Via Investor Brand Network
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives EU Approval to Launch EMBRACE Phase 3 MDD Study
Via Investor Brand Network
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Present at Canaccord Genuity Growth Conference
Via Investor Brand Network

Frequently Asked Questions

Is Cybin Inc. Common Shares publicly traded?
Yes, Cybin Inc. Common Shares is publicly traded.
What exchange does Cybin Inc. Common Shares trade on?
Cybin Inc. Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Cybin Inc. Common Shares?
The ticker symbol for Cybin Inc. Common Shares is CYBN on the New York Stock Exchange
What is the current price of Cybin Inc. Common Shares?
The current price of Cybin Inc. Common Shares is 6.030
When was Cybin Inc. Common Shares last traded?
The last trade of Cybin Inc. Common Shares was at 10/17/25 08:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.